Table 1 Synergistic combinations of fadraciclib and venetoclax.

From: Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells

Combination Index

Fraction Affected

no BCA medium

with BCA medium

del17p with BCA medium

#52

#54

#55

#52

#54

#55

#53

#56

#57

#77

0.5

4.1

0.1

0.04

3.0

0.6

1.0

0.5

0.6

0.03

0.003

0.75

1.8

0.1

0.1

1.0

0.5

0.8

0.5

0.5

0.003

0.0003

0.9

0.8

0.1

0.2

0.6

0.4

0.6

0.5

0.5

2.4E-04

5.0E-05

0.99

0.1

0.2

1.8

0.5

0.3

0.4

0.6

0.8

1.3E-06

2.0E-07

Dose Reduction Indexa for Fadraciclib

Fraction Affected

no BCA medium

with BCA medium

del17p with BCA medium

#52

#54

#55

#52

#54

#55

#53

#56

#57

#77

0.5

0.4

11.3

27.0

0.4

3.3

1.4

2.5

3.9

6374.2

660.3

0.75

0.8

12.6

10.7

2.0

3.9

2.0

2.2

3.0

1.9E + 05

2.8E + 04

0.9

1.7

14.1

4.3

10.0

4.7

2.8

2.0

2.4

5.8E + 06

1.2E + 06

0.99

9.1

18.0

0.6

326.3

7.0

3.5

1.7

1.4

9.7E + 09

4.0E + 09

Dose Reduction Indexa for Venetoclax

Fraction Affected

no BCA medium

with BCA medium

del17p with BCA medium

#52

#54

#55

#52

#54

#55

#53

#56

#57

#77

0.5

0.8

122.7

2192.0

1.9

3.5

3.4

10.4

2.9

34.0

965.2

0.75

1.9

58.8

1395.6

1.9

4.0

3.7

26.5

5.3

376.2

4492.0

0.9

4.5

28.1

888.5

1.9

4.5

4.0

67.7

9.4

4137.4

2.1E + 04

0.99

29.4

5.6

331.6

1.9

5.9

4.3

523.7

33.9

7.9E + 05

6.0E + 05

  1. aThe dose reduction index is a measure of how many fold the dose of each drug in a synergistic combination may be reduced, at a given effect level, compared with the doses of each drug alone.